Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesOverexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy
Breast Cancer Research and Treatment, 10/12/09
Kimet HS et al. – Overexpression of p53 is significantly associated with tamoxifen resistance in premenopausal women with breast cancer.
Methods- Data from 4,683 patients with cancer enrolled in two institutions between 1997 and 2006 analyzed
- Analyzed correlation between p53 overexpression and relapse, response to adjuvant therapy, breast cancer-specific survival (BCSS), and RFS in patients with primary breast cancer
- Overexpression of p53 was noted in 1,091 patients
- Significant correlation existed between p53 overexpression and poor prognostic factors, an increased frequency of regional recurrence, visceral metastasis, and worse BCSS and RFS
- Based upon subgroup analyses, combined age (<35, 35–50, and >50 years) and adjuvant therapy (hormone therapy only, chemotherapy only, and hormone therapy following chemotherapy), greatest reduction of survival based on p53 overexpression noted in patients 35–50 years of age who received hormone therapy following chemotherapy
- Multivariate analysis showed that p53 overexpression is independent prognostic factor in patients treated with hormone therapy and chemotherapy
- p53-overexpressing patients with breast cancer between 35 and 50 years of age who received tamoxifen following chemotherapy had greatest adverse effect on outcome
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
BMC Cancer, 12/04/09
A GTP cyclohydrolase 1 genetic variant delays cancer pain
Pain, 12/03/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice
Annals of Oncology, 12/04/09
Impact of biospecimens handling on biomarker research in breast cancer
BMC Cancer, 12/04/09
Effectiveness of a Home Care Nursing Program in the Symptom Management of Patients With Colorectal and Breast Cancer Receiving Oral Chemotherapy: A Randomized, Controlled Trial
Journal of Clinical Oncology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
European Journal of Cancer, 12/04/09
Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study
European Journal of Cancer, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor